Diffuse Large B-Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
MYD88-mutated diffuse large B-cell lymphoma had a significantly inferior 5-year overall survival than wild-type MYD88 diffuse large B-cell lymphoma (log-rank;P=0.019).
|
31123031 |
2020 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
MYD88 p.L265P and CD79B p.Y196C/H mutations were analyzed in diffuse large B-cell lymphoma (DLBCL) patients whose tumor samples were available (N = 29).
|
31436356 |
2019 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
MYD88 mutation was seen in 3.6% (2/55) of DLBCL cases, indicating a lower frequency in Indian de novo DLBCL.
|
29734251 |
2019 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
<i>Results</i>: MYD88 L265P mutations were detected in 22 of 29 samples from 14 patients with diffuse large B-cell lymphomas and one patient with lymphoplasmacytoid lymphoma.
|
31603365 |
2019 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Although inhibition of the mutated MYD88 pathway has an adverse impact on LPL/WM and DLBCL cell survival, its role in lymphoma initiation remains to be clarified.
|
31698464 |
2019 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Further co‑immunoprecipitation studies demonstrated that MYD88 bound to BTK in L265P‑DLBCL cells, and that this binding was abrogated following ST2825 treatment.
|
31432184 |
2019 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We highlight mechanisms by which the BCR cooperates with TLR9 and mutant isoforms of MYD88 to drive sustained NF-κB activity in the activated B-cell-like (ABC) subtype of DLBCL.
|
31402495 |
2019 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Testicular, breast, and uterine DLBCL (as well as possibly primary cutaneous DLBCL, leg-type) share a high prevalence of the non-germinal center B cell (non-GCB) phenotype and the MYD88/CD79B-mutated (MCD) genotype.
|
29931605 |
2018 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The link between inflammation and cancer is particularly strong in Waldenström macroglobulinemia (WM), a diffuse large B-cell lymphoma wherein the majority of patients harbor a constitutively active mutation in the innate immune-signaling adaptor myeloid differentiation primary response 88 (MyD88).
|
29358175 |
2018 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We therefore engineered BTK<sup>Cys481Ser</sup> and BTK<sup>WT</sup> expressing MYD88-mutated Waldenström macroglobulinemia (WM) and activated B-cell (ABC) diffuse large B-cell lymphoma (DLBCL) cells and observed reactivation of BTK-PLCγ2-ERK1/2 signaling in the presence of ibrutinib in only the former.
|
29496671 |
2018 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Review of our genetic data on diffuse large B cell lymphoma (DLBCL) and Waldenstrom macroglobulinemia (WM), found that a large percentage of DLBCL and WM cases that have a MYD88 mutation also harbor a TNFAIP3 loss, 55% DLBCL and 28% of WM, respectively.
|
30301877 |
2018 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In nearly all MYD88-wild-type DLBCL-LT, we found cancer-promoting mutations that either activate the NF-κB pathway through alternative genes (NFKBIE or REL) or activate other canonical cancer pathways (BRAF, MED12, PIK3R1, and STAT3).
|
29857068 |
2018 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
HSP110 sustains chronic NF-κB signaling in activated B-cell diffuse large B-cell lymphoma through MyD88 stabilization.
|
29871863 |
2018 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Recent studies demonstrated that in the activated B cell subtype of diffuse large B cell lymphoma (DLBCL), approximately one-third of the patients harbored somatically acquired MyD88 L265P mutation in their lymphomas.
|
30253331 |
2018 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
A missense mutation (L265P) changing leucine at position 265 to proline in MYD88 is found in ∼90% of Waldenström macroglobulinemia (WM) cases and in significant portions of activated B-cell diffuse large B-cell lymphomas and IgM monoclonal gammopathy of undetermined significance.
|
29703722 |
2018 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The recurrent MyD88 L265P mutation, present in 29% of ABC DLBCL, was reported as an independent poor prognostic factor for patients with newly diagnosed DLBCL.
|
28847710 |
2017 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We identified the MYD88 L265P somatic variant in cases with WM (39/42), MGUS (8/18), NHL (14/41, including 4/13 diffuse large B cell lymphoma (DLBCL), 1/8 mucosa-associated lymphoid tissue, 3/6 splenic marginal zone lymphoma (SMZL), 1/4 chronic lymphocytic leukemia, 2/3 nodal marginal zone lymphoma (NMZL), 1/2 mantle cell lymphoma, 1 Burkitt lymphoma, and 1 B cell NHL that could not be classified), primary AL (2/2), and IgM-PN (1/1).
|
28280994 |
2017 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Patients with primary breast and primary female genital tract diffuse large B cell lymphoma have a high frequency of MYD88 and CD79B mutations.
|
28803429 |
2017 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Finally, although the MYD88 L265P variant was not an independent prognostic factor in ABC DLBCL, associated <i>CD79B</i> mutations significantly improved the survival of MYD88 L265P-mutant ABC DLBCL in our cohort.<b>Conclusions:</b> This study highlights the relative heterogeneity of <i>MYD88</i>-mutant DLBCL, adding to the field's knowledge of the theranostic importance of <i>MYD88</i> mutations, but also of associated alterations, emphasizing the usefulness of genomic profiling to best stratify patients for targeted therapy.<i></i>.
|
27923841 |
2017 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The purpose of this study was to verify the existence of the important Myd 88 mutation and other immunohistochemical factors on disease prognosis in patients with DLBCL in southeast Serbia.
|
27837631 |
2017 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Notably, the MYD88 L265P mutation rates of CNS and testicular DLBCL patients were 60% and 77%, respectively.
|
28496180 |
2017 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
MYD88 and CD79B mutations were detected in 33% (13 patients) and 38% (15 patients), respectively, of the 40 patients with CD5<sup>+</sup> DLBCL.
|
27915469 |
2017 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Also, MYD88 L265P had little involvement in GI DLBCL compared with other extranodal DLBCLs, suggesting that its pathogenesis might be different from that of organs with a high frequency of MYD88 L265P.
|
27439595 |
2016 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
CARMA1- and MyD88-dependent activation of Jun/ATF-type AP-1 complexes is a hallmark of ABC diffuse large B-cell lymphomas.
|
26747248 |
2016 |
Diffuse Large B-Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We have now performed whole-exome sequencing for 41 tumor tissues of DLBCL-type PCNSL and paired normal specimens and also RNA-sequencing for 30 tumors, revealing a very high frequency of nonsynonymous somatic mutations in PIM1 (100 %), BTG2 (92.7 %), and MYD88 (85.4 %).
|
26757737 |
2016 |